{"entity":{"id":"pancan","kind":"collection","name":"Pancreatic Cancer Action Network (PanCAN)","aka":["PanCAN","src-pancan"],"tldr":"PanCAN is the leading pancreatic cancer patient organisation; it pioneered free tumour molecular profiling for patients (Know Your Tumor) and runs an adaptive platform trial for a disease with few options.","summary":"Founded 1999. Know Your Tumor showed that ~25% of pancreatic cancers have actionable alterations and that matched therapy improved survival (Pishvaian, Lancet Oncol 2020), influencing NCCN's recommendation for germline and somatic testing in all patients. Precision Promise is a Bayesian adaptive phase 2/3 platform (first readouts 2024). PanCAN's Patient Services provide free case management, clinical trial finder and dietitian access; its advocacy helped double federal pancreatic cancer research funding.","asOf":"2026-09-08","links":[{"label":"PanCAN","url":"https://pancan.org/"},{"label":"Know Your Tumor outcomes (Lancet Oncol 2020)","url":"https://doi.org/10.1016/S1470-2045(20)30074-7"},{"label":"PanCAN news","url":"https://pancan.org/news/"}],"tags":["gap-fill","patient-org","source","patient"],"related":["pancreatic","cgp","germline-testing","basket-umbrella-platform"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["tumour-agnostic"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-pishvaian-lancet-oncol"],"journals":[],"dependsOn":[],"notes":[],"url":"https://pancan.org/","holds":"Pancreatic cancer news, Patient Services case management, Know Your Tumor molecular profiling programme, Precision Promise adaptive platform trial, research grants and the annual 'State of the Science' reports.","license":"Copyright PanCAN","maintainer":"PanCAN"},"route":"/collections/pancan/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"},{"id":"germline-testing","kind":"technology","name":"Germline (hereditary) testing","route":"/technologies/germline-testing/"}],"term":[{"id":"basket-umbrella-platform","kind":"term","name":"Basket, umbrella, and platform trials","route":"/terms/basket-umbrella-platform/"},{"id":"tumour-agnostic","kind":"term","name":"Tumour-agnostic (tissue-agnostic) approval","route":"/terms/tumour-agnostic/"}],"paper":[{"id":"paper-rahib-projection-us-cancer-2040-jama-netw-open-2021","kind":"paper","name":"Estimated Projection of US Cancer Incidence and Death to 2040","route":"/key-papers/paper-rahib-projection-us-cancer-2040-jama-netw-open-2021/"},{"id":"paper-pishvaian-lancet-oncol","kind":"paper","name":"Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial","route":"/key-papers/paper-pishvaian-lancet-oncol/"}],"roadmap":[{"id":"pancreatic-roadmap","kind":"roadmap","name":"Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question","route":"/roadmaps/pancreatic-roadmap/"}],"institution":[{"id":"lustgarten-foundation","kind":"institution","name":"Lustgarten Foundation","route":"/institutions/lustgarten-foundation/"}],"trial":[{"id":"precision-promise","kind":"trial","name":"Precision Promise","route":"/trials/precision-promise/"}],"collection":[{"id":"pancan-know-your-tumor","kind":"collection","name":"PanCAN Know Your Tumor","route":"/collections/pancan-know-your-tumor/"}]}}